The Budget: Three Top Shares For A New ISA

Here’s how you could use your new £15,000 allowance!

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

ISAs are wonderful things, but why do they have to be so complicated?

Well, the Chancellor has taken a big stride in the right direction with the Budget this time!

budgetThe annual limit is to be raised further then expected — from 1 July, the allowance will be lifted from the old £11,520 to £15,000 per year.

And that nonsense about separate limits for shares and for cash has gone. You’ll be able to split the full £15,000 however you please, with the new rules applying to existing ISAs, too — previously, only half could be held in a cash ISA and the rest had to be in shares. Simplicity is a good thing — a lot of people are currently put off ISAs by seeing the rules as too complex.

Junior ISA limits are also to be raised — the old allowance of £3,720 is to be upped to £4,000 per year.

So, where should you stash the cash?

On the grounds that an ISA is best used for very long-term investing in solid companies, here are three that I think could be profitably stashed away and left to appreciate for a couple of decades:

GlaxoSmithKline

GlaxoSmithKlinePharmaceuticals is big business, and companies like GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have decades of profits ahead of them.

Take no notice of the naysayers who tell you the days of ‘Big Pharma’ are numbered and that the blockbuster-drugs model is coming to an end — it’s not going to happen any time soon. And even when new biotechnology developments come to the fore, who’s going to have the financial muscle to buy up the newcomers and develop their ideas?

Yes, the likes of GlaxoSmithKline, the UK’s biggest listed pharmaceutical firm by far.

Aviva

Insurance is a business that’s as old as the hills and will still be around long after you and I are gone. It can be a bit of a volatile business, but over the long term it has a habit of coming out ahead.

Most of the big insurers would make good ISA investments, but I like Aviva (LSE: AV) (NYSE: AV.US).

With a market cap of £15bn it’s big, it’s largely in the business of life insurance and long-term savings and investments, and it looks good value right now — and though we’re in it for the long term, there’s nothing wrong with taking advantage of short-term bargains.

Aviva had a tough run and had to slash its dividend, but there’s a period of growth expected, yields are still reasonable and the shares are on a forward P/E of only around 10.

TescoTesco

Finally, sticking some cash into the selling of food is another pretty safe bet. And it’s hard to beat the biggest in the business — Tesco (LSE: TSCO). It’s going through a lean spell, but it still accounts for around a third of the UK’s food shopping (and is pretty adept at non-food stuff, too), and it’s the only one of the big ones with significant overseas presence.

And with dividend yields of 5%, Tesco looks attractive.

Alan does not own any shares mentioned in this article. The Motley Fool owns shares in Tesco and has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Down 32% and with a P/E of 9.5, is this FTSE 250 share too cheap to ignore?

This FTSE 250 share is in freefall after slashing guidance for this financial year. But Royston Wild eyes a potential…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Growth Shares

Why high oil prices could be good news for Lloyds shares

Jon Smith talks through the implications of elevated oil prices and translates that through to the potential impact on Lloyds'…

Read more »

Investing Articles

Lists of income stocks to buy almost never include this one — but with a forecast 8.2% yield, I think they should!

This FTSE firm, not always seen as an income play, has a forecast yield of 8.2%, underlining why it's one…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Aviva’s share price is down 13% to under £7, despite outstanding 2025 results! Time for me to buy more?

I think Aviva’s share price reflects an outdated view of the business, and that gap between perception and reality is…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Shell’s £33+ share price is near an all-time high, so why am I going to buy more as soon as possible?

Shell's strong cash generation and improving growth drivers contrast with a share price well below my valuation, suggesting major long‑term…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

An 8.4% forecast yield but down 16%! Time for me to buy more of this FTSE 100 passive income star?

This FTSE 100 passive‑income machine is delivering rising payouts and strong forecasts, and its share price suggests the market hasn’t…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

£10,000 invested in Meta Platforms Stock 5 years ago is now worth…

Meta Platforms has been throwing good money after bad at Reality Labs since 2021, but the stock has more than…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£7,500 invested in Diageo shares 5 weeks ago is now worth…

Our writer wonders if Diageo shares are worth a look at a 14-year low, or whether this FTSE 100 spirits…

Read more »